Mary Kay Turner

VP PATIENT ADVOCACY AND GOVERNMENT AFFAIRS
Mary Kay Turner joined Cell-Gene company in August of 2017 as Vice President of Patient Advocacy and Government Affairs. Ms. Turner joins Cell-Gene company from Mitsubishi Tanabe Pharma America, where she led Patient Advocacy and Communications activity to support the commercialization of edaravone for ALS. She is a member of the Board of Directors for the ALS Hope Foundation. Mary Kay’s prior industry experience includes Head of State Government Affairs and Advocacy for Bristol-Myers Squibb. In this role, she led a team of government affairs professionals that focused on significant legislative and regulatory issues that promoted and protected the discovery and development of innovative therapies.
In 2016, Mary Kay was appointed to the Arizona Biomedical Research Commission by Arizona Governor Doug Ducey and served a one-year term. Additionally, she serves on the Board of Advisers for the International Cancer Advocacy Network (ICAN) and served on the Board of Directors for Mental Health America for 3 years.
Mary Kay has a BA in Political Science and History from the University of Oregon.
Scroll to Top

Hi
Here you can see some frequently asked questions or contact us!

What passage are your cells?

Our human mesenchymal stem/stromal cells (hMSCs) are provided at a population doubling level (PDL) of 8-10 post-mononuclear isolation (Bone Marrow; Equivalent Passage 2) or 14-18 post-isolation from the perivascular region of Wharton’s Jelly (Umbilical Cord; Equivalent Passage 3). Due to variabilities of seeding and harvest densities we characterize our MSC “True Age” in terms of their PDL.

How often should I feed your cells?

A: There is no need to feed cells between passages. Our media is engineered to be a batch culture media, where no media exchange or feed is necessary when following our suggested protocols.

Are your vials sold from pooled donors?

No, we do not pool donors at any time during our production. Master Cell Banks (MCBs) are created from each donor source. Working Cell Banks (WCBs) are produced from our MCBs for general product sales.

What characterization do you provide for your hMSCs?

We characterize our hMSCs by following ISCT criteria: cell identity (surface marker expression), functional potency (angiogenic cytokine and IDO secretion), and trilineage differentiation (adipo-, osteo-, and chondrogenesis). This information is provided to allow customers to choose the optimal hMSC tissue type and donor for their specific application or target indication.